A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Evaluation of the Safety and Efficacy of Once-Daily Administrations of TZP-102 for the Treatment of Symptomatic Gastroparesis in Patients with Diabetes Mellitus
Phase of Trial: Phase II
Latest Information Update: 17 Jun 2013
At a glance
- Drugs TZP 102 (Primary)
- Indications Diabetic gastroparesis
- Focus Therapeutic Use
- Sponsors Tranzyme Pharma
- 05 Oct 2012 Results presented at the 48th Annual Meeting of the European Association for the Study of Diabetes.
- 10 May 2011 Results presented at Digestive Disease Week 2011.
- 10 May 2011 Results presented at the Digestive Disease Week (DDW-2011).
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History